Regulators just legalized crypto-style stock futures in the US — long the exchanges that will host them

Verdict: Real approval, unproven fee stream — wait for listed-contract volume before paying up

The idea's long-term case — CFTC approval on November 3, 2026 moving stock perpetuals into regulated US venues where CME, IBKR and SCHW collect fees — is credible but not yet proven: none of the three has reported revenue attributable to the new contracts, and this evaluation could not be backtested because raw and adjusted price series for the three names used different bases. The strongest support is CME's cash machine, with FY2025 free cash flow of $4.19B, an operating margin in the 94th percentile of Financials peers, and dividends rising from $6.85 per share in 2021 to $10.05 in 2026. The strongest counter-evidence is insider posture and mixed fundamentals: provisional ownership records for the period ended September 30, 2026 show net open-market selling at all three names (about $21.5M at CME, $2.1M at IBKR, $34.4M at SCHW), and SCHW's Q4 2025 reported a net loss of $6.38B with negative free cash flow. Today's price readings argue against immediate entry anyway — CME is extended near $308 with RSI near 68, while IBKR at $77.88 sits below its 50-day EMA with RSI at 39, closer to damage than to a buy signal. This is a wait: treat the thesis as promising, not actionable, until listed contracts and volume confirm the fee stream. Numerical scoring is returned separately.

Trade now

**Wait.** The policy thesis — the CFTC's approval moving perpetual-style crypto contracts onto regulated US venues, where CME, IBKR, and SCHW collect fees on every trade — is an attractive idea on its own terms. But the entry conditions are not met today, so the business case and the trade are two separate questions right now. Scope note: this rule set was not backtestable — the historical comparison could not be computed because raw and adjusted price data for CME, IBKR, and SCHW used different bases. No historical trade statistics exist to support an immediate decision; the plan below rests on the supplied rules and current market readings only. The pivotal condition is the supplied EMA/RSI long-entry rule, which requires price and RSI (14) relative to 45 to line up in a consistent configuration against the 50-day EMA. As written, the rule lists both an "above" and a "below" version of the same conditions, so it cannot be fully satisfied in any state — treat any entry trigger with skepticism until the rule set is clarified. The closest live reading is IBKR at $77.88, below its 50-day EMA of $85.45, with RSI at 39.2 (below 45) as of the November 5, 2026 daily observation — only the weak-momentum half of the setup is in place. CME, by contrast, is extended: $308.27 versus a 50-day EMA of $283.63 and RSI near 68, meaning strong momentum rather than a pullback entry. The downside that matters: a drop through IBKR's $77 support or CME's $305.44 support would signal the pullback is deepening, not resolving. "Waiting" here means tracking whether the exchange and broker names pull back toward their 50-day EMAs with RSI cooling toward the mid-40s, while confirming the policy change translates into actual listed-contract volume — not chasing CME near its range high (about 5.6% below its 52-week high, but 41% above its range low). ### Technical details - **Entry rule (EMA/RSI Signal Long, each of CME@1d, IBKR@1d, SCHW@1d):** requires either (a) a close below the 50-day EMA with RSI (14) below 45, or (b) a close above the 50-day EMA with RSI (14) above 45. As supplied, both condition sets are bundled into one rule, making it internally inconsistent; live readings reflect each half separately. - **CME** (last close $308.27, daily, Nov 5, 2026): above-EMA leg met (50-day EMA at $283.63, a $24.64 distance); RSI (14) at 68.0 against the 45 threshold — a momentum reading above 50 generally signals a strong short-term trend, far from a pullback entry. Nearest support $305.44, resistance $309.52. - **IBKR** (last close $77.88, daily): below-EMA leg met (50-day EMA at $85.45, $7.57 above the price); RSI (14) at 39.2, below 45 — the bearish-half conditions are live. Nearest support $77.00, resistance $78.00. - **SCHW** (last close $93.37, daily): price sits $3.32 below its 50-day EMA of $96.69; RSI (14) at 62.3 — momentum too strong for the sub-45 leg, too weak for a clean trend signal. - **Exits (supplied):** MACD (12, 26, 9) crossing below its signal line; take-profit near the rank-2 resistance level; a hard stop at -2% and profit target at +4%; positions capped at 25% of the book with 2% fixed-risk sizing. MACD is a trend-momentum gauge; a cross below its signal line flags weakening momentum. CME's MACD currently reads +8.27 (bullish), while IBKR at -2.81 and SCHW at -2.68 are both negative. - No target or reward-to-risk calculation is offered because the entry rule cannot trigger as written and no backtested expectancy exists.

A firm regulatory catalyst lands on already-strong franchises

The regulatory approval documented in three same-day reports (The Block, Bloomberg, CoinDesk, all November 3, 2026) is a real, dated policy change, and the three named companies enter it from positions of financial strength — though the size of the incremental fee stream is not yet measurable in any reported numbers. ### The catalyst is a confirmed policy change, not speculation The idea's core claim rests on the CFTC approving individual stock perpetual futures in the US for the first time, and all three cited outlets reported it on November 3, 2026. Corroborated, same-day coverage reduces the risk that this is rumor; the thesis asks the reader to accept a structural shift of offshore leveraged trading into the regulated market, which is precisely the business CME and IBKR are built to capture. ### CME: a toll collector with extreme margins and cash conversion CME is the purest beneficiary because every contract routed through it generates a fee. The reported numbers support quality: FY2025 revenue of $6.52B grew 8.1% year over year, the operating margin of 61.8% sits in the 94th percentile of 355 Financials peers, and free cash flow of $1.10B in Q4 2025 ranks in the 96th percentile of 960 peers. Cash generation is durable — free cash flow has been positive every year since at least 2007 and reached $4.19B for FY2025. If perpetuals add even a modest volume stream, the incremental revenue lands on a fixed-cost platform and converts to cash at very high rates. ### IBKR: fastest growth plus broker-side capture IBKR sits on both sides of the trade as a broker routing into regulated venues. Reported Q4 2025 revenue of $667M grew 19.5% year over year — the 67th percentile among 774 peers — and quarterly momentum continued into 2026: Q2 revenue of $760M rose 8.7% from Q1, and net income of $1.34B rose 14.3%. A broker with accelerating client growth is well placed to onboard demand for…

Scores

• Conviction score breakdown: 56
• Thesis support: 68
• Trade readiness: 38
• Risk quality: 55
• Fundamentals trend: 62

Watch items

• IBKR — RSI (14)
• IBKR — Daily close vs support
• CME — RSI (14)
• CME — Daily close vs support
• SCHW — RSI (14)